#WCLC25: AstraZenecaâs Tagrisso combo extends survival by 10 months in...
The combination of AstraZenecaâs Tagrisso and chemotherapy cut the risk of death by 23% compared to Tagrisso alone for patients with advanced EGFR-mutant lung cancer. In the FLAURA2 study's key overall...
View ArticleRapport reveals promising open-label study data for epilepsy pill, heads to...
Rapport Therapeutics' shares {$RAPP} jumped 170% at market open Monday after it posted topline mid-stage data indicating that its epilepsy pill can cut seizure frequency. However, the trial was small...
View ArticleBiotech vet Harvey Berger steps into CEO role at Arena BioWorks
Less than two years after making their public debut, the founders of Arena BioWorks have tapped longtime biotech pro Harvey Berger to take over as CEO. And heâs just completed his first task by...
View ArticleBridgeBio's Phase 2 hypoparathyroidism data; FDA clears second pig kidney trial
Plus, news about Saol Therapeutics, Eisai, Takeda's Vonvendi, Junshi Biosciences, Belite Bio, Integra Therapeutics, Novonesis and Novo Nordisk: đ BridgeBioâs positive hypoparathyroidism results: The...
View ArticleExclusive: Cancer care startup Daymark Health raises $20M
Cancer care startup Daymark Health has raised $20 million in Series A funding less than half a year after its seed raise, Endpoints News learned exclusively. That's according to a securities filing...
View ArticleLB Pharma seeks $228M in proposed IPO with hopes to be industry's first since...
LB Pharmaceuticals, a biotech developing a twist on the decades-old schizophrenia treatment amisulpride, estimates it could gain net proceeds of $228 million from a Nasdaq IPO. The New York-based...
View Article#WCLC25: BioNTech, Bristol Myers tout PD-L1xVEGF results in small cell lung...
BioNTech and Bristol Myers Squibb said their PD-L1xVEGF drug used alongside chemotherapy showed promise in a mid-stage study for an aggressive form of lung cancer. In the Phase 2 trial, the companies...
View ArticleDianthusâ selective complement inhibitor yields Phase 2 success in myasthenia...
Dianthus Therapeutics on Monday shared positive mid-stage data in generalized myasthenia gravis for an antibody candidate that it believes has âpipeline-in-a-productâ potential for neuromuscular...
View ArticleEli Lillyâs Jaypirca shows âstrikingâ results in first-line lymphoma patientsÂ
Eli Lillyâs Jaypirca met the primary endpoint in a Phase 3 blood cancer trial, bringing the BTK inhibitor one step closer to a potential approval for previously untreated patients with a type of...
View ArticlePfizer reports new Covid-19 vaccine data from open-label study
Pfizer says a new formulation of its Covid-19 vaccine boosted antibody levels by at least four-fold in adults ahead of the upcoming respiratory season. The biopharma and Comirnaty co-developer BioNTech...
View ArticleNew FDA approval pathway for n-of-1 therapies coming soon, Prasad says
The success story of baby KJâs customized CRISPR therapy and the prospects for others like it have the FDA readying a new approval pathway for those with extremely limited treatment options. ...
View ArticleSummit plays defense for the first time as questions loom over Phase 3 data
Did Summit Therapeutics set expectations too high? Excitement has been building over its cancer drug ivonescimab over the last two years as the company, investors and clinicians all wondered if it...
View ArticleRidge Bio raises $25M to help drugmakers come up with better ADCs
A new California startup announced itself Tuesday with $25 million in seed funding, some major scientific backers, and the hope of helping biopharma companies make better antibody-drug conjugates and...
View ArticleNovartis to spend $1.4B on Tourmaline Bio, gaining new heart drug
Novartis said Tuesday that it would buy Tourmaline Bio for $1.4 billion in a bid to revitalize its cardiovascular offering. The Swiss pharma said it would pay $48 per share in ...
View ArticleEli Lilly offers AI models to biotechs with TuneLab launch
Eli Lilly is offering an unusual deal to any biotech: contribute some data, and in exchange, get access to many of Lilly's own AI models. The initiative, called TuneLab, debuted Tuesday with a dozen...
View ArticleRegeneronâs promising antibody for cat, birch allergies; Ascletis targets...
Plus, news about Anavex, Alnylam, Rapport Therapeutics, Dianthus Therapeutics, Ultragenyx, Atom Therapeutics, Alchemab, BioMarin, Amgen, Kyowa Kirin and Bristol Myers Squibb: 𤧠Regeneronâs allergy...
View ArticleIdeaya touts trio of cancer drugs as it eyes spot in precision oncology market
Ideaya Biosciences reiterated its goal of becoming a âglobal leaderâ in precision oncology over the next decade as it shared data from three early- to mid-stage cancer trials. Since its inception a...
View ArticleTrump may exempt some pharma products from tariffs in future trade deals
President Donald Trump is looking to strike more deals with trade partners and says he âmay be willingâ to exempt some pharmaceutical products from future tariffs. An executive order released last week...
View ArticleRegeneron and Sandoz patent deal clears path for Eylea biosimilar in 2026
Sandoz can sell its biosimilar version of Regeneronâs Eylea in the US by the end of 2026, following a patent settlement between the two companies. The generic drugmaker announced Tuesday that ...
View ArticleSamsung Bio secures $1.3B contract with âlarge-sizedâ US pharma customerÂ
Samsung Biologics has pulled in another billion dollar contract, this time with an unnamed âlarge-sizedâ US pharma company. The $1.3 billion contract started on Aug. 29 and will run until the end of...
View ArticleEric Green, who the Trump administration ousted from NIH, urges optimism
SAN DIEGO -- Thirty minutes into a speech extolling the achievements of genomic medicine, Eric Green addressed what he called the âelephant in the room": his forced departure as an NIH director. For 16...
View ArticleHHS outlines vaccine, drug strategy in new MAHA report
HHS on Tuesday unveiled its long-awaited Make America Healthy Again strategy report, including plans for changes to the childhood vaccine schedule, stricter oversight of how drugs are advertised to...
View ArticleLundbeck to transfer commercial drugs to three partners in 27 markets
Lundbeck will partner out its commercial medicines in 27 markets by the end of this year, the brain health drugmaker said Tuesday. The Danish biopharma is handing off ...
View ArticleEndpoints livestream: Will the XBI ever go up again?Â
Letâs talk about market structure! Now, before you yawn and click away, let me argue that this is one of the most important factors in how biotech stocks trade. How stocks get on the S ...
View Article